{rfName}

Indexed in

License and use

Icono OpenAccess

Citations

14

Altmetrics

Analysis of institutional authors

Saez De Gordoa KAuthorLopez IAuthorFrigola GAuthorMartinez DAuthorTeixido CCorresponding Author

Share

August 30, 2021
Publications
>
Article
Sí

Pd-l1 expression in non-small cell lung cancer: Data from a referral center in Spain

Publicated to:Diagnostics. 11 (8): 1452- - 2021-08-01 11(8), DOI: 10.3390/diagnostics11081452

Authors: de Gordoa, KS; Lopez, I; Marginet, M; Coloma, B; Frigola, G; Vega, N; Martinez, D; Teixido, C

Affiliations

August Pi & Sunyer Biomed Res Inst IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona 08036, Spain - Author
Hosp Clin Barcelona, Dept Pathol, Thorac Oncol Unit, Barcelona 08036, Spain - Author
Hospital Clinic Barcelona - Author
Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS - Author
See more

Abstract

Anti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC analyzed in our center between 2017 and 2020, as well as to correlate the expression values of the same patient in different tested samples. PD-L1 immunohistochemistry (IHC) was carried out on 1279 external and internal samples: 482 negative (tumor proportion score, TPS < 1%; 37.7%), 444 low-expression (TPS 1–49%; 34.7%) and 353 high-expression (TPS ≥ 50%; 27.6%). Similar results were observed with samples from our institution (N = 816). Significant differences were observed with respect to tumor histological type (p = 0.004); squamous carcinoma was positive in a higher proportion of cases than other histological types. There were also differences between PD-L1 expression and the type of sample analyzed (surgical, biopsy, cytology; p < 0.001), with a higher frequency of negative cytology. In addition, there were cases with more than one PD-L1 determination, showing heterogeneity. Our results show strong correlation with the literature data and reveal heterogeneity between tumors and samples from the same patient, which could affect eligibility for treatment with immunotherapy.

Keywords

chemotherapyimmunohistochemistryimmunotherapyligand 1 expressionlung cancermulticenternsclcopen-labelpd-l1pembrolizumabImmunohistochemistryImmunotherapyLung cancerNsclcPd-l1Specified final analysis

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Diagnostics due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 60/172, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine, General & Internal. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Clinical Biochemistry.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.44, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Oct 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-10-16, the following number of citations:

  • WoS: 5
  • Scopus: 4
  • Europe PMC: 4

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-10-16:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 9 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Saez de Gordoa Elizalde, Karmele) and Last Author (Teixidó Febrero, Cristina ).

the author responsible for correspondence tasks has been Teixidó Febrero, Cristina .